Flex Pharma Inc (NASDAQ:FLKS) – Analysts at Cantor Fitzgerald upped their FY2017 EPS estimates for Flex Pharma in a research note issued on Tuesday, according to Zacks Investment Research. Cantor Fitzgerald analyst M. Goldstein now anticipates that the biotechnology company will post earnings per share of ($2.18) for the year, up from their prior forecast of ($2.29).
A number of other brokerages also recently weighed in on FLKS. Piper Jaffray Companies set a $15.00 price target on shares of Flex Pharma and gave the stock a “buy” rating in a report on Tuesday, January 24th. Jefferies Group LLC reissued a “buy” rating and issued a $9.00 price target (down from $11.00) on shares of Flex Pharma in a report on Saturday, March 11th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $15.60.
Shares of Flex Pharma (NASDAQ:FLKS) traded down 13.97% on Thursday, reaching $3.08. 105,492 shares of the company traded hands. The company’s market capitalization is $51.66 million. Flex Pharma has a one year low of $3.05 and a one year high of $13.97. The firm has a 50-day moving average price of $4.10 and a 200 day moving average price of $5.49.
Flex Pharma (NASDAQ:FLKS) last announced its earnings results on Wednesday, March 8th. The biotechnology company reported ($0.48) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.84) by $0.36. The business had revenue of $0.30 million for the quarter, compared to analyst estimates of $0.09 million.
Large investors have recently added to or reduced their stakes in the stock. CAM Group Holding A S increased its stake in Flex Pharma by 50.0% in the third quarter. CAM Group Holding A S now owns 225,000 shares of the biotechnology company’s stock valued at $2,650,000 after buying an additional 75,000 shares during the period. Royce & Associates LP increased its stake in Flex Pharma by 3,000.0% in the fourth quarter. Royce & Associates LP now owns 68,200 shares of the biotechnology company’s stock valued at $360,000 after buying an additional 66,000 shares during the period. Finally, State Street Corp boosted its stake in shares of Flex Pharma by 0.5% in the fourth quarter. State Street Corp now owns 137,777 shares of the biotechnology company’s stock valued at $730,000 after buying an additional 642 shares in the last quarter. 31.36% of the stock is currently owned by institutional investors and hedge funds.
Flex Pharma Company Profile
Flex Pharma, Inc is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Flex Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flex Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.